Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine

Arthritis and Rheumatism

Volumn 46, Issue 4, 2002, Pages 1003-1013

  Chi, Chiu Mok ^a,b   Ho, Carmen Tze Kwan ^a   Kwok, Wah Chan ^a   Chak, Sing Lau ^a   Wong, Raymond Woon Sing ^a  

^a QUEEN MARY HOSPITAL   (Hong Kong)

^b TUEN MUN HOSPITAL   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CREATININE; CYCLOPHOSPHAMIDE; PREDNISONE;

ADULT; ARTICLE; CHRONICITY; CREATININE BLOOD LEVEL; DISEASE ACTIVITY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; KAPLAN MEIER METHOD; KIDNEY BIOPSY; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NEPHROTIC SYNDROME; OUTCOMES RESEARCH; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REGRESSION ANALYSIS; RELAPSE; REMISSION; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADMINISTRATION, ORAL; ADULT; AZATHIOPRINE; COHORT STUDIES; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; MALE; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PREVALENCE; PROGNOSIS; RECURRENCE; TREATMENT OUTCOME;

EID: 0036222849     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.10138     Document Type: Article

References (47)

1. Prognostic determinants in lupus nephritis: A long term clinicopathological study
2. Mortality risks associated with specific clinical manifestations of systemic lupus erythematosus
3. A comparison of the quality of life of patients with systemic lupus erythematosus with and without endstage renal disease
4. Cytotoxic drugs
5. Lupus nephritis in southern Chinese patients: Clinicopathological findings and long term outcome
6. The course and treatment of lupus nephritis
7. Lupus nephritis in children: A review of 167 patients
8. The prognosis of lupus nephritis in African-Americans: A retrospective analysis
9. Therapy of lupus nephritis: Controlled trial of prednisone and cytotoxic drugs
10. Long-term preservation of renal functions in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only
11. Treatment of lupus nephritis: A meta-analysis of clinical trials
12. Risk of sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy
13. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis
14. Intermittent intravenous cyclophosphamide therapy for lupus nephritis
15. Intravenous pulse cyclophosphamide in the treatment of type IV lupus nephritis
16. A controlled trial of pulse cyclophosphamide versus pulse methylprednisolone in severe lupus nephritis
17. Intravenous pulse cyclophosphamide treatment of severe lupus nephritis: A prospective five-year study
18. Treatment of acute systemic lupus erythematosus with intravenous infusions of cyclophosphamide: Value and limitations
19. New York University/Hospital for Joint Diseases experience with intravenous cyclophosphamide treatment: Efficacy in steroid unresponsive lupus nephritis
20. Treatment of lupus glomerulonephritis with intravenous cyclophosphamide
21. Clinical effects of intermittent, intravenous cyclophosphamide in severe systemic lupus erythematosus
22. Clinical, biochemical and pathological predictors of poor response to intravenous cyclophosphamide in patients with proliferative lupus nephritis
23. Cyclophosphamide therapy for lupus nephritis: Poor renal survival in black Americans
24. Intermittent intravenous cyclophosphamide arrests progression of the renal chronicity index in childhood systemic lupus erythematosus
25. Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide
26. Sequential therapy for diffuse proliferative and membranous lupus nephritis: Cyclophosphamide and prednisolone followed by azathioprine and prednisolone
27. Treatment of diffuse proliferative lupus glomerulonephritis: A comparison of two cyclophosphamide-containing regimens
28. The 1982 revised criteria for the classification of systemic lupus erythematosus
29. Outcome criteria for lupus nephritis trials: A critical overview
30. Prognostic factors in lupus nephritis: Contribution of renal histologic data
31. Role of pathology indices in the management of severe lupus glomerulonephritis
32. Outcome of acute glomerular injury in proliferative lupus nephritis
33. Mechanisms of progression of renal damage in lupus nephritis: Pathogenesis of renal scarring
34. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis
35. Treatment of membranous lupus nephritis with nephrotic syndrome by sequential immunosuppression
36. Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide
37. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis: A randomized, controlled trial
38. Cumulative rate of relapse of lupus nephritis after successful treatment with cyclophosphamide
39. "Nephritic flares" are predictors of bad long-term renal outcome in lupus nephritis
40. Factors predictive of outcome in severe lupus nephritis
41. Therapy with pulse methylprednisolone and short course pulse cyclophosphamide for diffuse proliferative glomerulonephritis
42. Lupus nephritis: Clinical and pathological correlation
43. Clinical status of patients after 10 years of lupus nephritis
44. A prospective study of survival and prognostic indicators of systemic lupus erythematosus in a southern Chinese population
45. Prognosis and treatment of systemic lupus erythematosus
46. Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis: Results of a pooled analysis
47. Long-term efficacy of azathioprine treatment for proliferative lupus nephritis